Advanced search    

Search: authors:"Shunichi Sugawara"

3 papers found.
Use AND, OR, NOT, +word, -word, "long phrase", (parentheses) to fine-tune your search.

Randomized Phase II Study of Docetaxel plus Personalized Peptide Vaccination versus Docetaxel plus Placebo for Patients with Previously Treated Advanced Wild Type EGFR Non-Small-Cell Lung Cancer

Koichi Takayama,1 Shunichi Sugawara,2 Yasuo Saijo,3 Makoto Maemondo,4 Atsushi Sato,5 Shinzo Takamori,6 Taishi Harada,7 Tetsuro Sasada,8 Tatsuyuki Kakuma,9 Junji Kishimoto,10 Akira Yamada,11 Masanori

Randomized Phase II Study of Docetaxel plus Personalized Peptide Vaccination versus Docetaxel plus Placebo for Patients with Previously Treated Advanced Wild Type EGFR Non-Small-Cell Lung Cancer

Koichi Takayama,1 Shunichi Sugawara,2 Yasuo Saijo,3 Makoto Maemondo,4 Atsushi Sato,5 Shinzo Takamori,6 Taishi Harada,7 Tetsuro Sasada,8 Tatsuyuki Kakuma,9 Junji Kishimoto,10 Akira Yamada,11 Masanori

EGFR T790M Mutation as a Possible Target for Immunotherapy; Identification of HLA-A*0201-Restricted T Cell Epitopes Derived from the EGFR T790M Mutation

Treatment with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib and erlotinib, has achieved high clinical response rates in patients with non–small cell lung cancers (NSCLCs). However, over time, most tumors develop acquired resistance to EGFR-TKIs, which is associated with the secondary EGFR T790M resistance mutation in about half the...